US OptionsDetailed Quotes
DMAC250516C5000
- 0.00
- 0.000.00%
15min DelayClose May 15 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV22.85%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.81Leverage Ratio--Theta--Rho--Eff Leverage--Vega
DiaMedica Therapeutics Stock Discussion
DiaMedica Nears Crucial Preeclampsia Trial Results: First Treatment Hope for Major Pregnancy Complication
●
KOL Event Scheduled for May 28, 2025 to Discuss the Disease of Preeclampsia and the Ongoing DM199 Phase 2 Study Design
●
Acute Ischemic Stroke Phase 2/3 Program Enrollment Progressing as Planned
DiaMedica's Dual Clinical Programs Show Progress as Cash Runway Extends to 2026
Revolutionary Stroke Treatment Mechanism Revealed: How DM199 Could Transform Patient Care
4 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
Scientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction
DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
Thursday, 20th February at 8:15 am
Scientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction
DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic dis...
2 MINUTES AGO, 8:27 AM EDT
VIA BUSINESSWIRE
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been...
DiaMedica Therapeutics Announces $11.8 Million Private Placement
NEWS
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
No comment yet